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particularly in mammary glands and uterus in females (see reviews in (26, 27) ). The proliferation of mammary glands is mainly dependent on estrogen stimulation; however, the proliferating epithelial cells detected in terminal end buds (TEBs) at the tip of elongating ducts in mammary glands are usually ER-negative (28) (29) (30) . Despite the unclear role of ER in this process, in mice with a homozygous disruption of ER genes, the mammary glands remain undeveloped as demonstrated by the lack of TEBs and alveolar structures, even though the serum estrogen level is 10 times higher than those in wild-type mice (31, 32) . This indicates an indispensable role of ER in the growth of mammary glands. Also, the fact that more than two thirds of breast cancers from patients are ER-positive and benefit from antiestrogen or ovariectomy therapies strengthens the importance of ER in the stimulation of cell growth in mammary glands in response to estrogen (33). Therefore, understanding the mechanisms involving the suppression of the ERmediated gene expression and cell proliferation may eventually help us to develop better drugs to battle the breast cancer.
In addition to functioning as a transcription regulator, TR2 can modulate other signaling via different mechanisms. For example, TR2 suppresses RXR-and RXR/RAR-mediated transcription by binding to the same DNA response element (DRE) with a higher binding affinity 8 TR2-#1, #2, and #3 plasmids were constructed by insertion of PCR-generated cDNA fragments corresponding to aa 1-112, aa , and aa 179-603, respectively, into pGEX-KG vector (a gift from Dr. Frank B. Furnari, University California-San Diego, CA). pCDNA3-TR2-fl AS and pIRES-TR2-N AS were constructed by insertion of opposite orientation of cDNAs encoding full length and N terminal (aa 1-112) into pCDNA3 (Invitrogen) and pIRES (Clontech), respectively.
Transient Transfections-Transfections and chloramphenicol acetyltransferase (CAT) assays
were performed using the calcium phosphate precipitation method, as described previously (37).
CAT reporter plasmids containing one copy of estrogen response element (ERE-CAT), or mouse mammary tumor virus (MMTV-CAT) were used as indicated. Also, a β-galactosidase expression plasmid, pCMV-β-gal, was used for transfection efficiency. For luciferase assay, luciferase reporters (ERE-luc and MMTV-luc) were transfected into cells using calcium phosphate precipitation method or SuperFect Transcription Reagent (Qiagen) as indicated. pRL-TK vector (Promega) encoding renilla luciferase was used for internal control and luciferase activity was analyzed using the Dual-Luciferase Reporter Assay System (Promega) following manufacturer's instructions.
Co-immunoprecipitation-MCF7 cells plated on 100-mm dishes were solubilized in 1 ml RIPA buffer containing 0.5% NP-40 and protease inhibitors. Immunoprecipitation was performed using rabbit anti-ER antibody (1:100) (H-184) and then analyzed by Western blotting with anti-ER (1:1000) (H-184) or anti-TR2 (1:1000) (G204) antibodies, followed by incubation with APconjugated goat anti-rabbit IgG or rabbit anti-mouse IgM antibodies, and visualized with Alkaline Phosphatase Conjugate Substrate Kit (Bio-Rad).
GST Pull-down Assay-GST alone and GST fusion proteins were purified by GlutathioneSepharose 4B beads as instructed by manufacturer (Amersham Pharmacia). The pull-down assay was performed with 5 µl of in vitro-translated [ 35 S]-labeled proteins as described previously (37).
Electrophoretic Mobility Shift Assay (EMSA)-EMSA was carried out as described previously (38) with some modifications. Human complement C3 ERE (containing one imperfect palindromic inverted repeat: 5′-AGGTGGCCCTGACCC-3′) end-labeled with γ−[
32 P]-ATP was used as probe. ER and TR2 were in vitro translated by TNT system (Promega) as instructed by manufacturer. Reactions were performed in 20 µl of EMSA binding buffer (10 mM HEPES/pH 7.9, 100 mM KCl, 1 mM Dithiothreitol, 0.5 mM EDTA, 2.5 mM MgCl 2 , and 6% glycerol). For the antibody supershift analysis, 1 µl of the monoclonal anti-ERα antibody (C-314) was used.
The protein-DNA complexes were analyzed on a 5% polyacrylamide native gel containing 2.5% glycerol in 1X TBE.
RESULTS

TR2 mRNA Is Expressed in the Breast Cancer Cell Lines-The studies of TR2 tissue distribution
have demonstrated that TR2 is expressed in many tissues with higher expression in brain and male reproductive organs (1, 2, 13, 14) . To explore TR2 roles in female tissues, the expression of TR2 mRNA was examined in several breast cancer cells using Northern blot analysis. As shown in Fig. 1 , TR2 transcripts around 2.5 kb were detected in three ER-positive breast cancer cell lines (MCF7, T47D, and ZR-75-1) at different expression levels. Also, TR2 transcripts could be detected in LNCaP and PC-3 prostate cancer cells as a control (Fig. 1 ).
TR2 Selectively Suppresses ER-mediated Transcription-ER is known to be an important
regulator for breast cancer development as two thirds of breast tumors contain a functional ER that mediates estrogen actions to stimulate cell growth. Since the TR2 was detected in the breast cancer cells, we wondered if TR2 could affect ER function. Using ERE-CAT reporter system, TR2 consistently suppressed either exogenous (in PC-3 and H1299 cells) or endogenous (in MCF7 and T47D cells) ER transactivation in a dose-dependent manner ( Fig. 2A) . To determine whether TR2 affects the expression of ER proteins, we used a stable clone of MCF7-TR2 cells, where the expression of FLAG-tagged TR2 driven by pBIG2i vector could be induced by doxycycline treatment (2 µg/ml) and detected by Western blotting with anti-FLAG antibody (Fig. 2B) . The expression of doxycycline-induced FLAG-TR2 was not influenced by 17β-estradiol (E2) treatment. After treating with doxycycline and/or E2, MCF7-TR2 cell lysates were subjected to co-immunoprecipitation followed by Western blotting using anti-ER antibody (H-184). As shown in Fig. 2B , although ER expression was reduced by E2 treatment, the expression level of ER was not suppressed by overexpressed FLAG-TR2 induced by doxycycline, indicating that the suppression of ER by TR2 does not result from the down-regulation of ER expression. We also found that, in transient transfection assay, both of endogenous and exogenous ER levels were not affected by transiently overexpressed TR2 in MCF7 and COS-1 cells (data not shown). Consistent with the phenomenon in Fig. 2A , ER was suppressed by doxycycline-induced TR2 in MCF7-TR2 cells (Fig. 2C) . By contrast, the doxycycline treatment did not affect ER transcriptional activity in the MCF7-pBIG cells, which were stably transfected with the pBIG2i parent vector (Fig. 2C ). To rule out the artificial effects linked to foreign reporters as demonstrated in Fig but not RXRα (Fig. 3B ). For testing ligand effects on the ER-TR2 binding, no much difference was found among different treatments (Fig. 3C) . Collectively, these results suggest that ER and TR2 are directly associated with each other in a ligand-independent manner.
To dissect the TR2 interaction domain on ER, six ER peptides fused with GST were tested in GST pull-down assays. As shown in Fig. 4A , GST-ER-#2 (aa 123-340) and GST-ER-#3 (aa 312-595), but not GST-ER-#1 (aa 1-165) and GST-ER-#4 (aa 552-595) can interact with TR2 in the presence or absence of E2. Furthermore, GST-ER-#6 (aa 312-340), the overlapping region between GST-ER-#2 and -#3, but not GST-ER-#5 (aa 123-312), showed positive interaction with TR2, indicating that ER-#6 domain is responsible for this interaction. On the other hand, three GST-fused TR2 fragments, GST-TR2-#1, -#2, and -#3, corresponding to N-terminus (aa 1-112), DBD (aa 88-196), and LBD (aa 179-603), respectively, were also examined to locate the ERbinding region. As shown in Fig. 4B , GST-TR2-#2, but not GST-TR2-#1 or -#3, was responsible for binding to ER.
Direct Association Is Required for TR2-mediated Suppression on ER-Small proteins (< 20~30
kD) are presumably capable of quickly crossing nuclear pore complexes through passive diffusion (39). Ideally, introducing small peptides containing interaction sequences may mask the binding sites for interaction proteins and prevent them from binding to the target proteins in either cytoplasm or nucleus. The small peptide ER-#6 was, therefore, tested to determine whether it can serve as an interaction blocker to interfere with ER-TR2 binding, using GST pulldown assay and mammalian two-hybrid system where in vitro translated HA-tagged ER-#6 and pCDNA3-HA-ER-#6 plasmid were introduced, respectively. Firstly, the interaction of GST-TR2
with [ 35 S]-labeled ER was inhibited by increasing amounts of HA-ER-#6 peptide (Fig. 5A ).
Secondly, GAL4-ER can interact with VP16-TR2 in the presence of E2, according to the induction of CAT activity, and this ER-TR2 interaction was suppressed when co-transfecting with pCDNA3-HA-ER-#6 (Fig. 5B) . Thus, based on these results, ER-#6 is able to be an interaction blocker. Next, to determine whether direct association is required for TR2 to suppress ER, pCDNA3-HA-ER-#6 was applied in an ERE-CAT reporter gene assay. As shown in Fig. 5C , the E2-induced ER transcription was significantly repressed by the doxycycline-induced TR2 in a dose-dependent fashion in MCF7-TR2 cells. Addition of ER-#6 was then capable of reversing this suppression, suggesting that TR2 suppresses ER through direct interaction.
The Biological Significance of TR2 on ER Activity-Antisense TR2 expression plasmids, pCDNA3-TR2-fl AS and pIRES-TR2-N AS, were assessed in ERE-luciferase assay to determine whether blocking endogenous TR2 expression might significantly enhance ER activity in MCF7 cells. First, using Western blotting with anti-TR2 antibody (G204), those two antisense constructs were proven to be able to reduce the expression of endogenous TR2 as well as overexpressed TR2 (Fig. 6A ). This reduction of endogenous TR2 by antisense plasmids resulted in an increase in ER transcription in a dose-dependent manner (Fig. 6B ), indicating that endogenous TR2 normally suppresses ER activity in MCF7 cells.
ER DNA-binding and Homodimeric Formation Are Disrupted by Associating with TR2-
To elucidate the molecular mechanisms by which ER was suppressed by interacting with TR2, we tested ER expression, stability, nuclear translocation, DNA binding, and interaction with coregulators. We found that overexpression of TR2 did not influence ER expression (Fig. 2B) , stability, or nuclear translocation (data not shown). Using GST pull-down assay and mammalian two-hybrid assay, TR2 did not affect the binding between ER and some coregulators such as SRC-1, TIF-II, and ARA70 (data not shown). After ruling out these mechanisms, we suspect that TR2 may mainly influence ER on DNA binding. Using the EMSA assay as shown in Fig.   7A , two specific ER-ERE bands could be detected (lane 3 and 4) and were supershifted by ER antibody (C-314) (lanes 5 and 6, indicated as an arrowhead). Two ER-ERE bands presumably consist of the monomer and dimer of ER bound to ERE, respectively. Since the sequences of ERE used in this assay contain one imperfect palindromic inverted repeat, the ER was bound to the half side of ERE as monomer. However, the monomer of ER bound to ERE does not occur in vivo due to the instability (40). Then, Addition of 100-fold molar excess of unlabeled ERE could effectively eliminate these specific bands (lanes 7 and 8). Interestingly, the intensity of these ER-ERE complexes were decreased upon addition of increasing amounts of TR2 in either the absence (lanes 9-11) or the presence of 10 nM E2 (lanes [12] [13] [14] . Since no ERE-TR2 specific band (lane 2) and no extra supershifted band formed as TR2-ER-ERE complexes (lanes 3-4 vs 9-14) were found, we may conclude that TR2 interacts with ER resulting in ER dissociating from binding to DNA. Accordingly, our competition assay (Fig. 7B) showed that the ER homodimer formation, as illustrated by the interaction between GST-ER-LBD and [ 35 S]-ER, was decreased by presence of TR2 and, conversely, heterodimeric formation of ER-TR2 was increased along with the increasing amounts of TR2. It indicates that TR2 forms a TR2-ER heterodimer but not a TR2-ER-ER complex to interfere with ER homodimeric formation. Furthermore, the reduction of ER homodimerization by TR2 could be rescued when the ER-#6 peptide which blocked TR2 from interacting with ER, was added (Fig. 7B ). Taken together, Fig. 7 suggests that TR2 may suppress ER-mediated transactivation via the formation of TR2-ER heterodimers that reduce the formation of the ER homodimer and cause ER to associate from ERE. 
TR2 Suppresses E2/ER-induced
DISCUSSION
The discovery that TR2 is expressed in breast cancer cells (Fig. 1) and suppresses ER-mediated signaling (Fig. 2) may demonstrate a novel biological function of TR2 in the estrogen-responsive organs, in addition to other potential physiological roles of TR2 in neurogensis and spermatogenesis (12) (13) (14) (15) . TR2 was originally identified as a transcriptional factor that can modulate target genes' expression via binding to the TR2 response elements (1, 2, 15) and also can influence the activity of other transcription factors, such as RXR, RAR, and TRα, through competing the same DNA response elements (15, 20) . In this study, we found that TR2 is capable of interacting and regulating ER-mediated transcription ( Fig. 2-4) . Furthermore, The interaction blocker, ER-#6, an ER fragment (aa 312-340) responsible for TR2 binding (Fig. 4A) , was able to rescue ER from suppression by TR2 (Fig. 5) , and administration of antisense TR2 could enhance ER transcription in MCF7 cells (Fig. 6) . Thus, these data provide a new molecular function of TR2 in modulating other nuclear receptor activity via the mechanism of direct protein-protein interactions, implying that TR2 may function as one of the repressors of ER-mediated signaling.
To further understand the molecular mechanisms by which TR2 suppresses ER, TR2 may possibly influence ER by changing the expression, protein stability, nuclear translocation, DNA binding, interacting with coregulators, and/or post-translational modifications such as phosphorylation and acetylation. From our preliminary studies, we found that TR2 neither affects ER expression levels (Fig. 2B ) and the nuclear translocation nor the interaction with some coactivators, such as SRC-1a, TIF-II, and ARA70 (data not shown). Despite not ruling out other possible mechanisms, such as post-translational modifications, data from EMSA ( Fig. 7A) clearly demonstrate that addition of TR2 may interrupt ER binding to DNA and this dissociation may be due to the disruption of ER homodimerization as a result of the formation of nonfunctional TR2-ER heterodimers (Fig. 7B) . It may consequently result in the suppression of ER transcription. Similarly, the disruption of ER homodimers through the interaction with truncated estrogen receptor product-1 (TERP-1) also shows an interruption of ER-ERE binding, resulting in the suppression of ER-mediated transcription (48). By contrast, a tumor suppressor, P53,
suppresses ER via interfering with the DNA binding without affecting the dimerization (49).
However, the mechanism by which p53 suppresses ER remains unclear.
Although it is still unknown whether the region spanning from aa 341 to 551 on ER provides the binding sites for TR2, the ER-#6 (aa 312-340) is sufficient to bind TR2 and functions as a interaction blocker (Fig. 4 & 5) . The ER-#6 covers the region spanning from helix However, they showed that the integrity of the LXXLL motif is still important for REA to perform its suppressive effect on ER, although it is not required for interaction. Therefore, it will be interesting to determine whether the LXXLL motif within TR2 is also necessary for suppression of the ER. heterodimers that result in ER dissociating from ERE.
ER is also known to function as a modulator to regulate the function of other nuclear receptors, such as TR, RAR, and RXR, through protein-protein interaction (60). ER also interacts with and suppresses proapoptotic forkhead transcription factor transcription activity in the presence of estrogen (61). Unexpectedly, we also found that ER could suppress TR2-mediated transcription in a ligand-independent manner (data not shown). This suppression was not mediated via interruption of TR2 DNA binding although the ER interaction site is located on TR2 DBD (data not shown). The mechanism by which ER suppresses TR2 remains unclear at this moment. Nevertheless, these findings represent a mutual regulation between ER and TR2 within the nuclear hormone receptor superfamily. Taken together, we suggest that TR2 may function not only a transcription factor, but also an important repressor in regulating ER-mediated transcription in mammary glands. Therefore, our future study may expand to determine the physiological roles of TR2 in TR2 knockout mice, especially in the development of mammary glands as well as brain, nervous, and reproductive systems where ER is known to exert an essential role. Relative mRNA expression amounts were normalized by 28S expression and quantitated by ImageQuant V.1.2 (Molecular Dynamics). E, Methods used are the same as described in (A).
ERE-and MMTV-luciferase reporter genes were used for examination of ER β and ΑR transactivation, respectively. MMTV-CAT reporter was used for PR and GR transactivation.
Luciferase activity was analyzed following manufacturer's instructions (Promega). 10 nM of E2, DHT, progesterone (P), and dexamethasone (Dex), were used as indicated. CAT and luciferase activity are presented relative to the response to ethanol, which is set as one. Values are the means ± SD of three independent experiments 
